UBS Group’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-4,429
| Closed | -$150K | – | 10789 |
|
|
2021
Q2 | $150K | Sell |
4,429
-40,268
| -90% | -$1.03M | ﹤0.01% | 5573 |
|
|
2021
Q1 | $1.04M | Buy |
44,697
+43,374
| +3,278% | +$1.31M | ﹤0.01% | 4202 |
|
|
2020
Q4 | $38K | Buy |
+1,323
| New | +$33.3K | ﹤0.01% | 6438 |
|
|
2020
Q3 | – | Sell |
-8
| Closed | – | – | 8675 |
|
|
2020
Q2 | $0 | Sell |
8
-2,641
| -100% | -$95.1K | ﹤0.01% | 8581 |
|
|
2020
Q1 | $83K | Sell |
2,649
-11,256
| -81% | -$391K | ﹤0.01% | 5445 |
|
|
2019
Q4 | $655K | Buy |
13,905
+1,912
| +16% | +$55.2K | ﹤0.01% | 4593 |
|
|
2019
Q3 | $77K | Buy |
11,993
+9,201
| +330% | +$76.8K | ﹤0.01% | 5923 |
|
|
2019
Q2 | $34K | Buy |
+2,792
| New | +$31.1K | ﹤0.01% | 6244 |
|
|
2019
Q1 | – | Sell |
-1,985
| Closed | -$8K | – | 8394 |
|
|
2018
Q4 | $8K | Buy |
1,985
+713
| +56% | +$4.3K | ﹤0.01% | 7377 |
|
|
2018
Q3 | $9K | Buy |
+1,272
| New | +$12.1K | ﹤0.01% | 7232 |
|
UBS Group's CNST Position: Q3 2021 in Review
UBS Group sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 4,429 shares — an estimated $150K sold.
UBS Group first reported a position in CNST in Q3 2018 and held it in 10 quarters. The position peaked at $1.04M in Q1 2021. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.
- UBS Group reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
- UBS Group sold 4,429 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $150K.
- UBS Group first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 10 quarters.
- UBS Group's Constellation Pharmaceuticals, Inc. position peaked at $1.04M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.
Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.